Related Experiment Video

Updated: Jul 27, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

GH and IGF1 in cancer therapy resistance

Reetobrata Basu1, John J Kopchick1,2,3

  • 1Edison Biotechnology Institute, Athens, Ohio, USA.

Endocrine-Related Cancer
|June 7, 2023
PubMed

Insights

Cancer treatment resistance is a major global challenge. This review explores how growth hormone (GH) and insulin-like growth factor 1 (IGF1) contribute to this resistance and discusses targeting GH-IGF1 for improved cancer therapy.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Cancer remains a leading cause of global mortality despite therapeutic advancements.
  • Treatment resistance, both intrinsic and acquired, significantly hinders therapeutic success.
  • Growth hormone (GH) and insulin-like growth factor 1 (IGF1) signaling pathways are implicated in cancer progression and resistance.

Approach:

  • This review synthesizes current scientific evidence on the role of GH and IGF1 in cancer therapy resistance.
  • It examines the mechanisms by which GH and IGF1 mediate resistance.
  • The review discusses the potential of targeting the GH-IGF1 axis for overcoming treatment resistance.

Key Points:

  • GH and IGF1 signaling are increasingly recognized as critical factors in the development of cancer therapy resistance.
  • Evidence links GH and IGF1 actions to intrinsic and acquired resistance to various cancer treatments.
  • Understanding these roles is crucial for developing novel therapeutic strategies.

Conclusions:

  • Targeting the GH-IGF1 axis presents a promising avenue for overcoming cancer treatment resistance.
  • Further research is needed to elucidate the full impact of GH-IGF1 and optimize inhibition strategies.
  • Exploiting GH-IGF1 inhibition could significantly improve outcomes for cancer patients facing resistance.
Keywords:
cancerchemoresistancegrowth hormone (GH)insulin-like growth factor 1 (IGF1)radioresistancetherapy resistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

938

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575